close

Agreements

Date: 2012-01-10

Type of information: Collaboration agreement

Compound: genetic biomarkers and potential companion diagnostics for select Sanofi oncology drug candidates

Company: Sanofi (France) Foundation Medicine (USA)

Therapeutic area: Cancer Oncology

Type agreement:

R&D

Action mechanism:

Disease: cancer

Details:

Foundation Medicine, has initiated a strategic collaboration with Sanofi. Foundation Medicine will use their genomic sequencing and analytic capabilities to identify genetic biomarkers and potential companion diagnostics for select Sanofi oncology drug candidates.  Foundation Medicine’s comprehensive cancer genomic test uses next-generation sequencing to analyze routine clinical specimens (i.e., small amounts of formalin fixed, paraffin embedded tumor tissue) for molecular alterations in approximately 200 cancer-related genes. The test is optimized for clinical-grade analysis of tumor tissues, overcoming multiple complexities (such as purity, ploidy, and clonality) inherent to tumor genomes. Test results are reported through a secure, interactive website linking genomic data to a structured knowledge base of relevant, publicly available scientific and medical information. The company also aims to provide information on relevant clinical trials to enable a more rapid recruitment of patients into trials for targeted therapies.

Financial terms:

Financial terms were not disclosed.

Latest news:

Is general: Yes